# Appello Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/appello-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Nashville, US
- Website: www.appellopharma.com
- Total disclosed funding: $11M
- Latest round: Series A (Jun 28, 2018)
- Investors on record: 2

## About

Appello Pharmaceuticals is a biotechnology firm focused on developing innovative therapeutic solutions for neurological disorders, leveraging advancements in neuroscience to improve the quality of life for patients.Appello Pharmaceuticals develops therapies for neurological conditions, including Alzheimer's and Parkinson's disease. Founded by Craig Lindsley, the company is based in Nashville, US. In June 2018, Appello completed a Series A funding round, raising USD 10.5 mn co-led by Deerfield Management and Mountain Group Partners. The total amount raised to date is USD 10.5 mn.Appello Pharmaceuticals specializes in innovative therapeutic solutions for neurological disorders. Their product pipeline includes drugs targeting diseases such as Alzheimer's, Parkinson's, and multiple sclerosis, with a focus on enhancing cognitive function and neuroprotection. The company collaborates with healthcare providers, hospitals, and research institutions across North America, Europe, and select Asian markets.Appello Pharmaceuticals generates revenue primarily through partnerships with healthcare providers and distributors. Their pharmaceutical products are delivered through direct sales agreements with hospitals and clinics, while they may also enter licensing agreements with larger pharmaceutical firms to broaden market reach. Revenue is derived from the sale of flagship products tailored to neurological conditions, although detailed pricing plans are not disclosed.Appello Pharmaceuticals aims to leverage its recent USD 10.5 mn Series A funding to further develop its pipeline of therapies targeting neurological disorders. The company plans to expand its market presence in North America and Europe, while also exploring opportunities in emerging Asian markets. Additionally, they are focused on launching new products developed from recent advancements in their research, with specific timelines yet to be announced.

## Funding rounds

- Series A, Jun 28, 2018, $11M — Mountain Group Partners, Deerfield Management

## Investors

- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A